French plan company payback on hepatitis C drug spending
This article was originally published in Scrip
The French authorities have some plans up their sleeve to curb spending on medicines, including an industry payback mechanism to regulate state spending on the new hepatitis C drugs such as Gilead's Sovaldi (sofosbuvir). Also on the cards are price cuts (savings of up to €550m) and greater use of generics and biosimilars (€465m).
You may also be interested in...
A legislative provision under which future COVID-19 vaccines can be made available in the UK before they are approved is also being used to offer an unlicensed flu vaccine that officials say has undergone full safety, efficacy and quality tests.
With product shortages made worse by the pandemic, companies in the UK are being asked to use a new system for notifying potential supply disruptions and any plans to discontinue specific medicines.
Two new projects have begun, one on standardizing the assessment of immune responses in individuals vaccinated in clinical trials, the other to improve understanding of potential immunity in patients who have been infected with SARS-CoV-2.